4-acetyl-N-cyclopropylbenzenesulfonamide | 620986-49-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-acetyl-N-cyclopropylbenzenesulfonamide
• CAS: 620986-49-4
• 化学式: C₁₁H₁₃NO₃S
• mdl: MFCD05270405
• 分子量: 239.295
• InChiKey: ZTAUEPZRKPEAKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-acetyl-N-cyclopropylbenzenesulfonamide 在 potassium carbonate 作用下， 以 乙醇 、 水 、 丙酮 为溶剂， 生成 N-cyclopropyl-4-(1-(2-(2,4-difluorophenyl)-2-oxoethyl)-4-methyl-2,5-dioxoimidazolidin-4-yl)benzenesulfonamide
  参考文献：
  名称：

  Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors

  摘要：

  In search of novel drugs against tuberculosis, we previously discovered and profiled a novel hydantoin-based family that demonstrated highly promising in vitro potency against Mycobacterium. tuberculosis. The compounds were found to be noncovalent inhibitors of DprE1, a subunit of decaprenylphosphoryl-beta-D-ribose-2'-epimerase. This protein, localized in the periplasmic space of the mycobacterial cell wall, was shown to be an essential and vulnerable antimycobacterial drug target. Here, we report the further SAR exploration of this chemical family through more than 80 new analogues. Among these, the most active representatives combined submicromolar cellular potency and nanomolar target affinity with balanced physicochemical properties and low human cytotoxicity. Moreover, we demonstrate in vivo activity in an acute Mtb infection model and provide further proof of DprE1 being the target of the hydantoins. Overall, the hydantoin family of DprE1 inhibitors represents a promising noncovalent lead series for the discovery of novel antituberculosis agents.

  DOI：

  10.1021/acs.jmedchem.0c00107
• 作为产物：
  描述：

  4-乙酰基苯磺酰氯 、 环丙胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以75%的产率得到4-acetyl-N-cyclopropylbenzenesulfonamide
  参考文献：
  名称：

  新型变构蛋白二硫化物异构酶抑制剂的设计、合成和生物学评价。

  摘要：

  蛋白质二硫键异构酶 (PDI) 负责内质网 (ER) 中的新生蛋白质折叠，对胶质母细胞瘤的存活至关重要。为了提高 PDI 抑制剂 BAP2 (( E)-3-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)benzonitron) 的效力，我们设计并合成了 67 种类似物。我们确定 PDI 抑制依赖于查耳酮支架的 A 环羟基，并且磺酰胺链中 cLogP 的增加提高了效力。对接研究表明，BAP2 和类似物与 PDI 的 b' 结构域中的 His256 结合，而 His256 突变为 Ala 会消除 BAP2 类似物的活性。BAP2 和优化的类似物 59 具有适度的硫醇反应性；然而，我们建议 BAP2 类似物对 PDI 的抑制取决于 b' 结构域。重要的是，类似物抑制胶质母细胞瘤细胞生长，诱导 ER 应激，增加 G2M 检查点蛋白的表达，降低 DNA 修复蛋白的表达。总的来说，我们的结果支持抑制

  DOI：

  10.1021/acs.jmedchem.8b01951

文献信息

• Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors
  作者：Suhui Yang、Andrea Shergalis、Dan Lu、Anahita Kyani、Ziwei Liu、Mats Ljungman、Nouri Neamati

  DOI：10.1021/acs.jmedchem.8b01951

  日期：2019.4.11

  survival. To improve the potency of lead PDI inhibitor BAP2 (( E)-3-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)benzonitrile), we designed and synthesized 67 analogues. We determined that PDI inhibition relied on the A ring hydroxyl group of the chalcone scaffold and cLogP increase in the sulfonamide chain improved potency. Docking studies revealed that BAP2 and analogues bind to His256 in the b' domain of

  蛋白质二硫键异构酶 (PDI) 负责内质网 (ER) 中的新生蛋白质折叠，对胶质母细胞瘤的存活至关重要。为了提高 PDI 抑制剂 BAP2 (( E)-3-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)benzonitron) 的效力，我们设计并合成了 67 种类似物。我们确定 PDI 抑制依赖于查耳酮支架的 A 环羟基，并且磺酰胺链中 cLogP 的增加提高了效力。对接研究表明，BAP2 和类似物与 PDI 的 b' 结构域中的 His256 结合，而 His256 突变为 Ala 会消除 BAP2 类似物的活性。BAP2 和优化的类似物 59 具有适度的硫醇反应性；然而，我们建议 BAP2 类似物对 PDI 的抑制取决于 b' 结构域。重要的是，类似物抑制胶质母细胞瘤细胞生长，诱导 ER 应激，增加 G2M 检查点蛋白的表达，降低 DNA 修复蛋白的表达。总的来说，我们的结果支持抑制
• Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-<scp>d</scp>-Ribose Oxidase (DprE1) Inhibitors
  作者：Olga Balabon、Eleni Pitta、Maciej K. Rogacki、Eugenia Meiler、Ruth Casanueva、Laura Guijarro、Sophie Huss、Eva Maria Lopez-Roman、Ángel Santos-Villarejo、Koen Augustyns、Lluis Ballell、David Barros Aguirre、Robert H. Bates、Fraser Cunningham、Monica Cacho、Pieter Van der Veken

  DOI：10.1021/acs.jmedchem.0c00107

  日期：2020.5.28

  In search of novel drugs against tuberculosis, we previously discovered and profiled a novel hydantoin-based family that demonstrated highly promising in vitro potency against Mycobacterium. tuberculosis. The compounds were found to be noncovalent inhibitors of DprE1, a subunit of decaprenylphosphoryl-beta-D-ribose-2'-epimerase. This protein, localized in the periplasmic space of the mycobacterial cell wall, was shown to be an essential and vulnerable antimycobacterial drug target. Here, we report the further SAR exploration of this chemical family through more than 80 new analogues. Among these, the most active representatives combined submicromolar cellular potency and nanomolar target affinity with balanced physicochemical properties and low human cytotoxicity. Moreover, we demonstrate in vivo activity in an acute Mtb infection model and provide further proof of DprE1 being the target of the hydantoins. Overall, the hydantoin family of DprE1 inhibitors represents a promising noncovalent lead series for the discovery of novel antituberculosis agents.